Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-pubmed-20260406-062122-b65f8ebc_task_73907230",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\"ranked_hypotheses\":[{\"title\":\"C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages\",\"description\":\"C1Q binding to modified LDL particles triggers Syk kinase signaling and mitochondrial ROS production, providing a priming signal for NLRP3 inflammasome assembly in lesional macrophages. This mechanism creates a feed-forward inflammatory loop where C1Q-opsonized cholesterol crystals activate caspase-1, driving IL-1β/IL-18 secretion and perpetuating plaque inflammation. The hypothesis leverages the CANTOS trial precedent for IL-1β-targeted therapy in atherosclerosis, offering a clear translational path via repurposing the Syk inhibitor fostamatinib.\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.65,\"novelty\":0.58,\"feasibility\":0.72,\"therapeutic_potential\":0.68,\"mechanistic_plausibility\":0.60,\"druggability\":0.65,\"safety_profile\":0.55,\"competitive_landscape\":0.62,\"data_availability\":0.70,\"reproducibility\":0.60},\"composite_score\":0.64,\"evidence_for\":[{\"claim\":\"Syk kinase links complement activation to NLRP3 inflammasome signaling\",\"pmid\":\"19370150\"},{\"claim\":\"Cholesterol crystals activate NLRP3 inflammasome in atherosclerotic macrophages\",\"pmid\":\"20393552\"},{\"claim\":\"C1Q induces mitochondrial ROS in macrophages providing second signal\",\"pmid\":\"30396994\"},{\"claim\":\"IL-1β pathway validated in CANTOS cardiovascular outcomes trial\",\"pmid\":\"28903622\"}],\"evidence_against\":[{\"claim\":\"Cholesterol crystals alone are sufficient for NLRP3 activation without C1Q\",\"pmid\":\"20393552\"},{\"claim\":\"NLRP3, ASC, IL-1β deficiency shows only modest 20-30% lesion reduction\",\"pmid\":\"NA - general NLRP3 KO literature\"},{\"claim\":\"C1Q positioning as signal 1 for NLRP3 priming is non-standard\",\"pmid\":\"NA - mechanistic critique\"}]},{\"title\":\"C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation\",\"description\":\"C1Q binding to macrophages via CD91/TLR2 heterodimers triggers NF-κB and STAT1 signaling, upregulating SR-A and CD36 scavenger receptors. This creates a feed-forward loop where C1Q-opsonized oxLDL internalization drives foam cell formation, which subsequently produces more C1Q. The mechanism connects the biomarker finding directly to disease progression and offers multiple druggable nodes (CD91, SR-A, CD36).\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.58,\"novelty\":0.62,\"feasibility\":0.70,\"therapeutic_potential\":0.72,\"mechanistic_plausibility\":0.55,\"druggability\":0.62,\"safety_profile\":0.48,\"competitive_landscape\":0.60,\"data_availability\":0.65,\"reproducibility\":0.55},\"composite_score\":0.62,\"evidence_for\":[{\"claim\":\"C1Q enhances LDL uptake by monocytes\",\"pmid\":\"15488903\"},{\"claim\":\"C1Q modulates macrophage TLR signaling through CD91/TLR2 crosstalk\",\"pmid\":\"33585041\"},{\"claim\":\"CD36 contributes to foam cell formation and atherosclerosis\",\"pmid\":\"17110344\"},{\"claim\":\"SR-A and CD36 are established foam cell markers with therapeutic relevance\",\"pmid\":\"Multiple established\"}],\"evidence_against\":[{\"claim\":\"C1Q binding to TLR2/6 is not well-established; C1Q canonically engages calreticulin/CD91 or gC1qR\",\"pmid\":\"NA - mechanistic critique\"},{\"claim\":\"C1Q could represent compensatory enhanced cholesterol clearance rather than pathological drive\",\"pmid\":\"NA - alternative interpretation\"},{\"claim\":\"SR-A and CD36 are upregulated by oxLDL via PPARγ/LXR independent of C1Q\",\"pmid\":\"Multiple established\"}]},{\"title\":\"C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion\",\"description\":\"Chronic hyperactivation of classical complement in the atherosclerotic intima leads to C1S-mediated opsonization of late apoptotic foam cells, but paradoxically blocks efficient clearance. C5b-9 membrane attack complex deposition on surviving cells causes secondary necrosis, releasing cholesterol crystals and DAMPs that amplify local inflammation and expand the necrotic core. The hypothesis requires C1Q to 'flip' from its known homeostatic role to pathological at high lesional concentrations.\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.55,\"novelty\":0.55,\"feasibility\":0.68,\"therapeutic_potential\":0.65,\"mechanistic_plausibility\":0.50,\"druggability\":0.60,\"safety_profile\":0.52,\"competitive_landscape\":0.58,\"data_availability\":0.60,\"reproducibility\":0.55},\"composite_score\":0.60,\"evidence_for\":[{\"claim\":\"Botto M et al. establishes C1q role in apoptotic cell clearance\",\"pmid\":\"16205503\"},{\"claim\":\"C1q binds apoptotic cells via calreticulin/CD91\",\"pmid\":\"24639361\"},{\"claim\":\"Defective efferocytosis promotes necrotic core formation in murine atherosclerosis\",\"pmid\":\"19841018\"},{\"claim\":\"C1S inhibitors exist in complement drug development pipelines\",\"pmid\":\"Multiple pharmaceutical sources\"}],\"evidence_against\":[{\"claim\":\"C1Q is canonically a promoter of efferocytosis, not an inhibitor - hypothesis inverts known role\",\"pmid\":\"16205503\"},{\"claim\":\"C1Q deficiency causes defective clearance and autoimmunity, opposite direction\",\"pmid\":\"16205503\"},{\"claim\":\"C1q-/- mice on hypercholesterolemic backgrounds have not consistently shown protection\",\"pmid\":\"NA - implicit falsification\"},{\"claim\":\"Mechanistic threshold model for C1Q 'flip' not proposed\",\"pmid\":\"NA - mechanistic gap\"}]},{\"title\":\"C1Q-Angiogenic Axis Promoting Plaque Neovascularization\",\"description\":\"Macrophage-secreted C1Q binds to endothelial gC1qR/CD91 receptors, activating src/FAK/ERK1/2 signaling to upregulate VEGFR2 and promote VEGF-independent angiogenesis. This drives unstable microvessel formation prone to hemorrhage, contributing to plaque progression and vulnerability. The hypothesis connects lesional macrophage infiltration to intraplaque hemorrhage and clinical instability.\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.55,\"novelty\":0.60,\"feasibility\":0.55,\"therapeutic_potential\":0.58,\"mechanistic_plausibility\":0.52,\"druggability\":0.42,\"safety_profile\":0.45,\"competitive_landscape\":0.52,\"data_availability\":0.58,\"reproducibility\":0.50},\"composite_score\":0.53,\"evidence_for\":[{\"claim\":\"C1Q induces angiogenic program in endothelial cells independent of VEGF\",\"pmid\":\"24453254\"},{\"claim\":\"gC1qR identified as C1Q receptor on endothelium\",\"pmid\":\"8006586\"},{\"claim\":\"Neovascularization correlates with plaque instability in human atherosclerosis\",\"pmid\":\"12403663\"},{\"claim\":\"Angiogenesis is clinically validated as therapeutic target for plaque stabilization\",\"pmid\":\"Multiple established\"}],\"evidence_against\":[{\"claim\":\"gC1qR is a widely expressed chaperone, not a canonical signaling receptor\",\"pmid\":\"NA - mechanistic critique\"},{\"claim\":\"VEGF independence claim contradicts stated VEGFR2 upregulation mechanism\",\"pmid\":\"NA - internal inconsistency\"},{\"claim\":\"No direct evidence links C1Q to intraplaque hemorrhage\",\"pmid\":\"NA - translational gap\"},{\"claim\":\"No drug-like small molecules targeting gC1qR available\",\"pmid\":\"NA - druggability challenge\"}]},{\"title\":\"Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent\",\"description\":\"Recombinant C1-esterase inhibitor (Ruconest) blocks C1R/C1S proteolytic activity, preventing classical pathway activation without affecting lectin or alternative pathways. This reduces opsonization of apoptotic cells, C5b-9 formation, and downstream inflammatory cytokine production, promoting a more stable plaque phenotype. The hypothesis leverages an already-approved biologic with established safety data.\",\"target_gene\":\"C1R/C1S\",\"dimension_scores\":{\"evidence_strength\":0.52,\"novelty\":0.48,\"feasibility\":0.58,\"therapeutic_potential\":0.62,\"mechanistic_plausibility\":0.52,\"druggability\":0.58,\"safety_profile\":0.50,\"competitive_landscape\":0.55,\"data_availability\":0.55,\"reproducibility\":0.52},\"composite_score\":0.53,\"evidence_for\":[{\"claim\":\"C1-INH mechanism and clinical use established for hereditary angioedema\",\"pmid\":\"18692500\"},{\"claim\":\"C1-INH reduces inflammation in ischemia-reperfusion models\",\"pmid\":\"34712720\"},{\"claim\":\"C1Q identified as atherosclerosis risk gene in index paper\",\"pmid\":\"38179058\"},{\"claim\":\"C1-INH is FDA-approved with established safety profile\",\"pmid\":\"Multiple regulatory sources\"}],\"evidence_against\":[{\"claim\":\"C1-INH has broad effects beyond C1R/C1S (kallikrein, FXIIa, plasmin)\",\"pmid\":\"18692500\"},{\"claim\":\"Classical pathway blockade may shunt activation to lectin/alternative pathways\",\"pmid\":\"NA - compensatory mechanism\"},{\"claim\":\"Hereditary angioedema patients on C1-INH lack reported atherosclerosis outcomes\",\"pmid\":\"NA - clinical data gap\"},{\"claim\":\"Acute 8-week administration may not model decades-long human disease development\",\"pmid\":\"NA - temporal mismatch\"}]},{\"title\":\"NETosis Amplification by C1Q in Plaque Neutrophils\",\"description\":\"C1Q serves as a neutrophil chemoattractant and potentiates NETosis in response to cholesterol crystals. C1Q-opsonized NETs become nidus for C3b/iC3b deposition, recruiting additional immune cells and forming immune complexes that perpetuate plaque inflammation. This links neutrophil recruitment to complement amplification and plaque progression.\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.45,\"novelty\":0.55,\"feasibility\":0.52,\"therapeutic_potential\":0.50,\"mechanistic_plausibility\":0.45,\"druggability\":0.50,\"safety_profile\":0.48,\"competitive_landscape\":0.52,\"data_availability\":0.50,\"reproducibility\":0.48},\"composite_score\":0.50,\"evidence_for\":[{\"claim\":\"C1Q promotes NETosis in neurological disease models\",\"pmid\":\"34620133\"},{\"claim\":\"NETs accelerate atherosclerotic plaque progression\",\"pmid\":\"31740993\"},{\"claim\":\"C1Q-coated structures enhance complement activation cascades\",\"pmid\":\"35294448\"},{\"claim\":\"PAD4 inhibitors in preclinical development for NETosis-targeted therapy\",\"pmid\":\"Multiple pharmaceutical sources\"}],\"evidence_against\":[{\"claim\":\"Primary citation is neuroinflammation context - neutrophils in brain differ from plaque\",\"pmid\":\"34620133\"},{\"claim\":\"C5aR-like receptor for C1Q on neutrophils hypothesized but not identified\",\"pmid\":\"NA - receptor identification gap\"},{\"claim\":\"Cholesterol crystals alone potently induce NETosis; C1Q contribution unclear\",\"pmid\":\"Multiple established\"},{\"claim\":\"NETs predominantly in early-to-mid lesions; C1Q more associated with advanced plaques\",\"pmid\":\"NA - temporal mismatch\"}]},{\"title\":\"C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis\",\"description\":\"Atherosclerotic inflammation increases circulating IL-6 that crosses the compromised blood-brain barrier, priming cerebral endothelial cells to express C1Q. Brain microglia upregulate C1QC in response, driving complement-mediated synaptic pruning and cognitive decline. This mechanistic chain connects peripheral C1Q-driven atherosclerosis severity to neurodegeneration and vascular dementia.\",\"target_gene\":\"C1QA/C1QC\",\"dimension_scores\":{\"evidence_strength\":0.40,\"novelty\":0.70,\"feasibility\":0.42,\"therapeutic_potential\":0.52,\"mechanistic_plausibility\":0.38,\"druggability\":0.40,\"safety_profile\":0.42,\"competitive_landscape\":0.48,\"data_availability\":0.45,\"reproducibility\":0.40},\"composite_score\":0.47,\"evidence_for\":[{\"claim\":\"Systemic complement activation links to neuroinflammation\",\"pmid\":\"24107782\"},{\"claim\":\"C1Q mediates synapse loss in neurodegeneration models\",\"pmid\":\"32393358\"},{\"claim\":\"Cardiovascular risk drives microglial activation\",\"pmid\":\"36218221\"},{\"claim\":\"C1Q involved in developmental synaptic pruning - disease relevance plausible\",\"pmid\":\"Multiple established\"}],\"evidence_against\":[{\"claim\":\"Causal chain contains at least 4 unproven steps\",\"pmid\":\"NA - mechanistic critique\"},{\"claim\":\"IL-6 crossing BBB is context-dependent; sufficiency unproven\",\"pmid\":\"NA - BBB assumption critique\"},{\"claim\":\"CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis\",\"pmid\":\"NA - model mismatch\"},{\"claim\":\"C1Q expression patterns differ between mice and humans in CNS\",\"pmid\":\"Multiple species comparison studies\"},{\"claim\":\"Longest causal chain with weakest direct evidence for atherosclerosis\",\"pmid\":\"NA - synthesis critique\"}]}],\"knowledge_edges\":[{\"source_id\":\"H1_Efferocytosis\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"proposes_pathological_role_in\"},{\"source_id\":\"H1_Efferocytosis\",\"source_type\":\"hypothesis\",\"target_id\":\"C1S\",\"target_type\":\"gene\",\"relation\":\"mechanistic_intermediate_for\"},{\"source_id\":\"H1_Efferocytosis\",\"source_type\":\"hypothesis\",\"target_id\":\"C5B9\",\"target_type\":\"complex\",\"relation\":\"downstream_effector_of\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"priming_signal_from\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"SYK\",\"target_type\":\"kinase\",\"relation\":\"signaling_intermediate_of\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"NLRP3\",\"target_type\":\"inflammasome\",\"relation\":\"activates_inflammasome\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"IL1B\",\"target_type\":\"cytokine\",\"relation\":\"upstream_regulator_of\"},{\"source_id\":\"H3_Angiogenesis\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"ligand_source_of\"},{\"source_id\":\"H3_Angiogenesis\",\"source_type\":\"hypothesis\",\"target_id\":\"GPIBA\",\"target_type\":\"receptor\",\"relation\":\"receptor_for\"},{\"source_id\":\"H3_Angiogenesis\",\"source_type\":\"hypothesis\",\"target_id\":\"VEGFR2\",\"target_type\":\"receptor\",\"relation\":\"upregulated_by\"},{\"source_id\":\"H4_FoamCell\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"autocrine_prime_by\"},{\"source_id\":\"H4_FoamCell\",\"source_type\":\"hypothesis\",\"target_id\":\"CD91\",\"target_type\":\"receptor\",\"relation\":\"receptor_for\"},{\"source_id\":\"H4_FoamCell\",\"source_type\":\"hypothesis\",\"target_id\":\"CD36\",\"target_type\":\"receptor\",\"relation\":\"upregulates\"},{\"source_id\":\"H4_FoamCell\",\"source_type\":\"hypothesis\",\"target_id\":\"MSR1\",\"target_type\":\"receptor\",\"relation\":\"upregulates\"},{\"source_id\":\"H5_NETosis\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"amplifies\"},{\"source_id\":\"H5_NETosis\",\"source_type\":\"hypothesis\",\"target_id\":\"PAD4\",\"target_type\":\"enzyme\",\"relation\":\"activates\"},{\"source_id\":\"H6_Neurodegeneration\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"systemic_driver_of\"},{\"source_id\":\"H6_Neurodegeneration\",\"source_type\":\"hypothesis\",\"target_id\":\"IL6\",\"target_type\":\"cytokine\",\"relation\":\"intermediate_mediator_of\"},{\"source_id\":\"H6_Neurodegeneration\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QC\",\"target_type\":\"gene\",\"relation\":\"upregulated_in_microglia\"},{\"source_id\":\"H7_C1INH\",\"source_type\":\"hypothesis\",\"target_id\":\"C1R\",\"target_type\":\"protease\",\"relation\":\"inhibits\"},{\"source_id\":\"H7_C1INH\",\"source_type\":\"hypothesis\",\"target_id\":\"C1S\",\"target_type\":\"protease\",\"relation\":\"inhibits\"},{\"source_id\":\"H7_C1INH\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"blocks_activation_of\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"H4_FoamCell\",\"target_type\":\"hypothesis\",\"relation\":\"shares_nfkb_pathway_with\"},{\"source_id\":\"H2_NLRP3\",\"source_type\":\"hypothesis\",\"target_id\":\"H1_Efferocytosis\",\"target_type\":\"hypothesis\",\"relation\":\"converges_on_il1b_with\"},{\"source_id\":\"H3_Angiogenesis\",\"source_type\":\"hypothesis\",\"target_id\":\"H1_Efferocytosis\",\"target_type\":\"hypothesis\",\"relation\":\"both_contribute_to_plaque_destabilization\"},{\"source_id\":\"Source_Paper\",\"source_type\":\"publication\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"identifies_as_risk_gene\"},{\"source_id\":\"Source_Paper\",\"source_type\":\"publication\",\"target_id\":\"C1QC\",\"target_type\":\"gene\",\"relation\":\"identifies_as_risk_gene\"}],\"synthesis_summary\":\"The integration of therapeutic, skeptical, and feasibility perspectives identifies the C1Q-triggered NLRP3 inflammasome hypothesis (composite score 0.64) and C1Q-induced foam cell formation hypothesis (0.62) as the top-ranked priorities for mechanistic investigation and therapeutic development. The NLRP3 axis benefits from the strongest translational precedent (CANTOS trial validation of IL-1β targeting in cardiovascular disease) and an immediate repurposing opportunity via the FDA-approved Syk inhibitor fostamatinib, with the triple knockout C1qa−/−Nlrp3−/−LDLR−/− mouse representing the critical falsifying experiment. The foam cell hypothesis offers a more direct connection between the biomarker finding and disease progression, with multiple druggable nodes (CD91, SR-A, CD36), though safety concerns around metabolic disruption require careful evaluation. The efferocytosis hypothesis, while mechanistically compelling, is undermined by its inversion of C1Q's known physiological role and lack of direct C1Q-atherosclerosis data; the fundamental unresolved question—whether C1Q serves as a causal driver or a compensatory biomarker of complement-consuming inflammation—must be addressed via C1q−/− mouse experiments on hypercholesterolemic backgrounds before substantial resource commitment to any hypothesis. Hypotheses 5-7 (NETosis, neurodegeneration, C1-INH repurposing) represent lower priority targets given weaker direct evidence, longer causal chains, or significant druggability/regulatory challenges, though the C1-INH path offers an accelerated repurposing route given existing FDA approval for hereditary angioedema.\"}",
  "tokens_used": "4315",
  "persona_id": "persona-synthesizer"
}